XML 173 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense $ 2.3 $ 4.0 $ 13.7 $ 19.1
Cost of Commercial Product sales | Total Product sales, net        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense 0.0 0.0 0.0 0.1
Cost of Commercial Product sales | MCM Product sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense 0.3 1.0 1.6 3.5
Cost of Commercial Product sales | Total Bioservices revenues        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense (0.1) 0.2 0.2 0.8
R&D        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense 0.0 0.6 1.0 1.7
Selling, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense $ 2.1 $ 2.2 $ 10.9 $ 13.0